Search Results 1781-1790 of 21398 for anti-TNF drugs

1. Antibiotic Therapies Clinical Trials - Mayo Clinic Research

   The purpose of this study is to describe the results of antibiotic resistant organisms after the use of topical antibiotics in the treatment of chronic ...

2. Gastric acid suppression medications increase risk for recurrence of Clostridium difficile infection - Mayo Clinic News Network

   C-diff is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. The study is published in JAMA Internal ...

3. Acetylcysteine (Inhalation Route) Description and Brand Names - Mayo Clinic

   Description and Brand Names. Drug information provided by: Merative, Micromedex®. US Brand Name. Mucomyst. Descriptions. Acetylcysteine is a ...

4. Hodgkin lymphoma (Hodgkin disease) - Care at Mayo Clinic

   Mayo Clinic radiation oncologists plan and deliver radiation therapy safely using advances such as volumetric modulated arc therapy and proton therapy. These ...

5. A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus - Mayo Clinic

   drug. 2. Previous anti-cancer hormonal treatment or anti-cancer immunotherapy within 2 weeks of the first administration of trial drug. 3. Previous treatment ...

6. Teriparatide (Subcutaneous Route) Side Effects - Mayo Clinic

   Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

7. Formoterol (Inhalation Route) Description and Brand Names - Mayo Clinic

   Formoterol is used together with other medicines (eg, inhaled corticosteroids) to treat asthma and prevent bronchospasm in patients with asthma. When used ...

8. Glofitamab-Gxbm (Intravenous Route) Description and Brand Names - Mayo Clinic

   Description and Brand Names. Drug information provided by: Merative, Micromedex®. US Brand Name. Columvi. Descriptions. Glofitamab-gxbm injection is used to ...

9. A Study of Mogamulizumab Combined with Nivolumab in Patients who have Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   Has any unresolved toxicity grade > 1 from previous anti-cancer therapy. Subject use of immunosuppressive medication within 14 days before the Cycle 1 Day 1:.

10. Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer - Mayo Clinic

    Participation eligibility · Cisplatin ineligibility is defined as meeting one of the following criteria: · Anti PD-1/PD-L1 therapy administered as part of ...